Luyao Sun specialises in Multifunctional Layered Double Hydroxide Nanoparticles for Cancer Therapy

The complexity and diversity of tumors pose considerable challenges in the search for desirable therapeutics. One of the current focuses in clinical anti-cancer investigations is to shift from monotherapy to combination therapy, which aims to achieve enhanced efficacy under synergistic interactions among individual therapeutic modalities. Moreover, many versatile medical imaging techniques utilizing fluorescence, ultrasound, or magnetic resonance imaging (MRI) have enabled the early diagnosis of cancer and accurate location of tumors. There is a pressing demand to develop novel theranostic platforms, which can realize combination therapy under the synergism of multitherapeutics and allow precise tumor detection and treatment under cooperative imaging guidance. Luyao Sun is focusing on developing layered double hydroxide nanoparticles as a nanoplatform to treat cancer.

​2018.10-2022.10: Ph.D. candidate at The University of Queensland, under the supervision of Prof. Zhi Ping (Gordon) Xu; 

2018.4-2018.9: Research Assistant in Southern University of Science and Technology, under the supervision of Prof. Qiongyu Guo; 

2015.9-2018.4: M.S. in South China University of Technology, under the supervision of Prof. Xiaofeng Chen; 

2011.9-2015.7: B.S. in Wuhan University of Technology, under the supervision of Prof. Yu Li